Learn the key warning signs of prostate cancer that men often overlook. Early awareness can make all the difference.

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...

The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...

A new drug for advanced prostate cancer has shown promise in early trials experts have said, with the medication shrinking tumors in some patients. Prostate cancer is the most common cancer among men ...

CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.

Q: Recently, a 47-year-old asymptomatic patient had a random prostate-specific antigen (PSA) level of 5.32 ng/mL. A repeat assay the following day was 6.10. All previous PSAs over a seven-year period ...

Despite medical advances and increased awareness campaigns, many men continue postponing essential prostate treatment. Health care providers identify several key factors contributing to these ...

Metastatic castration-resistant prostate cancer (mCRPC) is a severe form of late-stage disease where the tumor can no longer be controlled with hormone therapy. Even in such situations, effective ...

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.